Press Releases

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

Press Releases /

Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the granting of a $3.0M award from the Medical Technology Enterprise Consortium (MTEC).  The MTEC project award will support the upcoming Phase 1 human safety studies of […]

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004 Read More »

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Press Releases /

Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced today that it has received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium (MTEC) and the BrightFocus Foundation. Astrocyte is developing AST-004, a potential therapy for traumatic

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury Read More »

Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations

Press Releases /

Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today that Lisa Manna has joined Astrocyte as the Vice-President of Clinical Development Operations.  Ms. Manna brings extensive experience in clinical and development operations, working with contract research

Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations Read More »

Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

Press Releases /

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the completion of the Company’s Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004, based upon technology originally licensed from The University

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic Read More »

Astrocyte Pharmaceuticals Announces Expanded Clinical Advisory Board

Press Releases /

Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board (CAB) with leading stroke and traumatic brain injury (TBI) clinical experts.   The Board will be Chaired by current advisor Dr. Jeffrey L. Saver, and include ongoing advisor Dr. David W.

Astrocyte Pharmaceuticals Announces Expanded Clinical Advisory Board Read More »

Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference

Press Releases /

Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in Los Angeles demonstrating the efficacy of AST-004 in a non-human primate (NHP) model of stroke.  Dr. Theodore Liston, Vice President of Research at Astrocyte, presented the talk entitled, “Significant Efficacy

Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference Read More »

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board

Press Releases /

Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory Board and will chair the company’s Clinical Advisory Board. Astrocyte Pharmaceuticals is developing small molecule therapeutics for the treatment of brain injuries, including patients who have suffered a

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board Read More »

Astrocyte Pharmaceuticals Awarded $3M NIH Small Business Grant to Advance TBI and Concussion Therapeutic

Press Releases /

Cambridge, MA, September 19, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a $3 million Phase 2 Small Business Innovation Research (SBIR) Grant from the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH).  The grant provides funding to advance

Astrocyte Pharmaceuticals Awarded $3M NIH Small Business Grant to Advance TBI and Concussion Therapeutic Read More »

Astrocyte Pharmaceuticals Awarded Alzheimer’s Disease Research Grant

Press Releases /

Cambridge, MA, September 18, 2018 – Astrocyte Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has been awarded $287k Phase 1 Small Business Technology Transfer (STTR) Grant from the National Institutes of Health’s (NIH) National Institute On Aging (NIA).  The grant provides funding to further evaluate and advance its promising neuroprotectant drug

Astrocyte Pharmaceuticals Awarded Alzheimer’s Disease Research Grant Read More »

Astrocyte Pharmaceuticals Completes $2.3M Pre-A Financing Round

Press Releases /

Cambridge, MA, June 6, 2018 – Astrocyte Pharmaceuticals Inc. announced today that it has completed a Pre-A financing round that raised over $2.3M.  The company is advancing several small molecule neuroprotective therapeutics for the treatment of stroke, traumatic brain injury (TBI) or concussion, and neurodegenerative disease. The Pre-A round was led by Kaitai Capital, and

Astrocyte Pharmaceuticals Completes $2.3M Pre-A Financing Round Read More »

Privacy Policy

Sign up for Updates
By using this website, you agree to our use of cookies. We use cookies to improve your browsing experience. To learn more about the cookies we use, see our Privacy Policy.